A Case of Malignant Lymphomas that Healed
Completely After Oral Administrations of
4-Hydroxybenzaldehyde
Volume 1 - Issue 5
Kimihiko Okazaki*
Received: May 26, 2018; Published: June 08, 2018
DOI: 10.32474/OAJOM.2018.01.000124
Full Text
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
In 1969, Mutsuyuki Kochi [1,2] developed 4-Hydroxybenzaldehyde for use as a novel anti-tumor agent without side effect and
acquired its patent. Accordingly, this medicine is capable of preventing carcinogenesis when used in sufficient quantity. To treat
advanced cancers, an oncologist should start with giving the cancer patient a small dose of the 4-Hydroxybenzaldehyde to avoid the
possible severe hemorrhage of a tumor caused by excessive necrosis. Therefore, it has useful applications in treating lymphomas
and leukemia’s. Consequently, those who have these diseases can receive a considerably large dose of the medicine. The mechanism
of action of the medicine is apparently competitive inhibition of tyrosine kinase, which is the rate-limiting enzyme in the pathway
of carcinogenesis [3,4].
Abstract|
Case Report|
References|